Claims for Patent: 9,371,392

Summary for Patent: 9,371,392

Title:	Treatment of complex regional pain syndrome using denosumab
Abstract:	Disclosed herein are methods of treating pain using comprising RANK/RANKL antagonists.
Inventor(s):	Tabuteau; Herriot (New York, NY)
Assignee:	ANTECIP BIOVENTURES II LLC (New York, NY)
Application Number:	14/952,724
Patent Claims:	1. A method of treating pain comprising parenterally administering denosumab to relieve pain in a human being in need thereof, wherein the pain results from complex regional pain syndrome (CRPS). 2. The method of claim 1, wherein the denosumab is administered subcutaneously. 3. The method of claim 2, wherein about 120 mg of denosumab is administered to the human being over a four week period. 4. The method of claim 1, wherein the denosumab is administered intravenously. 5. The method of claim 4, wherein about 0.05 mg/kg to about 3 mg/kg of denosumab is administered to the human being over a four week period. 6. The method of claim 5, wherein about 1.1 mg/kg to about 2.5 mg/kg of denosumab is administered to the human being over a four week period. 7. The method of claim 6, wherein about 30 mg to about 180 mg of denosumab is administered weekly to the human being for two to four weeks. 8. The method of claim 1, wherein the denosumab is administered intramuscularly. 9. The method of claim 1, wherein the denosumab is administered intradermally. 10. The method of claim 1, wherein about 0.05 mg/kg to about 3 mg/kg of denosumab is administered to the human being over a four week period. 11. The method of claim 1, wherein about 1 mg/kg to about 3 mg/kg of denosumab is administered to the human being over a three to five week period. 12. The method of claim 1, wherein about 1.1 mg/kg to about 2.5 mg/kg of denosumab is administered to the human being over a three to five week period. 13. The method of claim 1, wherein about 1.1 mg/kg to about 2.5 mg/kg of denosumab is administered to the human being over a four week period. 14. The method of claim 1, wherein about 30 mg to about 180 mg of denosumab is administered to the human being no more than once a week. 15. The method of claim 14, wherein the human being experiences pain relief for at least 3 hours after administration of denosumab. 16. The method of claim 14, wherein the human being experiences pain relief for at least 24 hours after administration of denosumab. 17. The method of claim 14, wherein the human being experiences pain relief for at least one week after administration of denosumab. 18. The method of claim 1, wherein about 100 mg to about 140 mg of denosumab is administered to the human being over a three to five week period. 19. The method of claim 1, wherein about 120 mg of denosumab is administered to the human being over a four week period. 20. The method of claim 1, wherein, within a period of about six months, about 0.1 mg/kg to about 20 mg/kg of denosumab is administered to the human being. 21. The method of claim 1, wherein, within a period of about six months, about 0.5 mg/kg to about 2 mg/kg of denosumab is administered to the human being. 22. The method of claim 1, wherein the human being experiences pain relief for at least 3 hours after administration of denosumab. 23. The method of claim 1, wherein the human being is about 10 years old to about 90 years old. 24. The method of claim 1, wherein denosumab is administered in at least two separate doses. 25. The method of claim 24, wherein the second dose is administered at 5.times.T.sub.max or greater. 26. The method of claim 24, wherein the second dose is administered within one year of the first dose. 27. The method of claim 1, wherein denosumab is administered in a liquid composition comprising about 0.0001% (w/v) to about 50% (w/v) of denosumab. 28. The method of claim 1, wherein about 5 mg to about 100 mg of denosumab is administered per dose. 29. The method of claim 28, wherein denosumab is administered in a pharmaceutical composition comprising a carrier, an excipient, a buffer, an antioxidant, or a diluent. 30. The method of claim 1, wherein denosumab is administered in a pharmaceutical composition comprising a carrier, an excipient, a buffer, an antioxidant, or a diluent.

Details for Patent 9,371,392

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	PROLIA	denosumab	Injection	125320	06/01/2010		2034-06-11
Amgen, Inc.	XGEVA	denosumab	Injection	125320	11/18/2010		2034-06-11